“A saliva-based diagnostic test that can detect HPV-related head and neck cancer has the potential to catch the disease earlier and even serve as a standard screening method, which the medical community currently lacks. Oropharyngeal squamous cell carcinoma, a cancer caused by human papillomavirus that develops in the mouth and throat, is expected to cause more than 10,000 deaths this year, according to the American Cancer Society. Cases have been increasing significantly in men in recent years.” Read the full…
“An experimental blood test accurately detected HPV-linked head and neck cancer recurrence and confirmed when patients remained cancer-free, according to findings from a study led by University of North Carolina Lineberger Comprehensive Cancer Center researchers Read the full article at the UNC Lineberger Comprehensive Cancer Center.
“Newswise — Using a new blood test that’s in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.” Read the full article on Newswise.com.
“A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).” Read the full article on Astro.org.
“CHAPEL HILL – A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.” Read the full article on Eurekalert.org.
Naveris Congratulates Scientific Advisors Bhisham Chera and Gaorav Gupta on Presentation of Clinical Data at the 2018 ASTRO Annual Meeting
“WALTHAM, Mass., Oct. 22, 2018 /PRNewswire/ — Naveris, Inc., a private biotechnology company developing blood tests for early cancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D., scientific advisors and co-chairs of its Scientific Advisory Board, and announces the presentation of clinical trial data at the American Society for Radiation Oncology annual meeting being held October 21 to October 24, 2018, in San Antonio, TX.” Read the full article on PRNewsWire.com.